Kolmar BioTech KRX:215380KOSDAQ
우정바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked1since Sep 11
In Q2 2026, Kolmar BioTech reported revenue of ₩11.0bn, up 55.0% year on year, and an operating loss of ₩19m. Kolmar BioTech (우정바이오) appeared in 0 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 22 with 1 article.
Kolmar BioTech quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩11.0bn | +55.0% | −₩19m margin −0.2% | ₩3.4bn |
| Q1 2026 | ₩11.0bn | +32.7% | ₩429m margin 3.9% | −₩211m |
| Q4 2025 derived | ₩12.4bn | +3.9% | −₩13m margin −0.1% | −₩1.3bn |
| Q3 2025 | ₩9.8bn | +5.7% | −₩874m margin −9.0% | −₩616m |
| Q2 2025 | ₩7.1bn | -40.2% | −₩1.6bn margin −22.7% | −₩1.5bn |
| Q1 2025 | ₩8.3bn | -18.2% | −₩1.4bn margin −16.9% | −₩2.1bn |
| Q4 2024 derived | ₩12.0bn | -33.2% | ₩1.0bn margin 8.5% | ₩513m |
| Q3 2024 | ₩9.2bn | +90.5% | ₩622m margin 6.7% | −₩1.0bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Kolmar BioTech top stories 2 weeks, by number of outlets
- 1